Switching from OxyContin to M-Eslon (Methadone)
Methadone should only be prescribed by experienced clinicians due to its complex pharmacokinetics, highly variable conversion ratios (1:5 to 1:12 from oral morphine), long half-life, and risk of serious adverse effects including cardiac arrhythmias and respiratory depression. 1
Indications for Opioid Switching
Switch from OxyContin (oxycodone) to methadone when: 1, 2
- Inadequate analgesia despite appropriate dose escalation of oxycodone
- Unmanageable adverse effects that cannot be controlled with symptomatic therapies
- Cost considerations, as methadone is significantly less expensive 1
- Renal impairment (eGFR <30 mL/min), since methadone is excreted fecally rather than renally 2
Critical Conversion Considerations
Conversion Ratios
The conversion from oxycodone to methadone requires two-step calculation: 1, 3
- First convert oxycodone to oral morphine equivalents using 1:1.5 ratio (oxycodone is 1.5x more potent than morphine) 3
- Then convert morphine to methadone using ratios of 1:5 to 1:12 or higher, depending on the prior opioid dose 1
The conversion ratio is dose-dependent: higher baseline opioid doses require more conservative ratios (approaching 1:12 or greater). 1
Dose Reduction for Incomplete Cross-Tolerance
Reduce the calculated methadone dose by 25-50% to account for incomplete cross-tolerance between opioids. 3 This is critical because methadone's unique pharmacology creates asymmetric tolerance patterns. 3
Switching Protocol
Step-by-Step Approach
Use a 3-day switch protocol followed by one-week titration period: 4
- Calculate the equianalgesic methadone dose using the two-step conversion above
- Reduce this calculated dose by 25-50% for safety 3
- Initiate methadone while tapering oxycodone over 1-3 days 4
- Titrate methadone dose over the following week based on pain control and adverse effects 4
- Provide immediate-release opioid for breakthrough pain at 5-20% of total daily morphine equivalent dose 2
Monitoring Requirements
Evaluate patients within 24-48 hours initially, then weekly during titration: 3
- Pain intensity and functional status
- Opioid-related adverse effects (sedation, respiratory depression, nausea)
- Cardiac monitoring for QT prolongation, as methadone carries arrhythmia risk 1, 5
- Signs of inadequate analgesia requiring dose adjustment 3
Special Populations and Contraindications
Renal Impairment
Methadone is preferred in severe renal disease (stages 4-5, eGFR <30 mL/min) because it is excreted fecally, unlike oxycodone which accumulates renally. 2, 3
Cardiac Risk
Screen for cardiac disease and QT prolongation before initiating methadone. Consider baseline ECG, especially in patients with: 5
- Pre-existing cardiac conduction abnormalities
- Concurrent QT-prolonging medications
- Electrolyte abnormalities
Hepatic Impairment
Use additional caution and longer dosing intervals in hepatic dysfunction, as decreased clearance can lead to toxic accumulation. 3
Common Pitfalls to Avoid
- Never use full equianalgesic ratios without dose reduction - incomplete cross-tolerance is universal 1, 3
- Do not start with extended-release formulations - use immediate-release methadone for initial titration 3
- Avoid switching without adequate trial of first opioid - ensure proper dose titration of oxycodone has been attempted first 3
- Do not overlook methadone's long half-life (24-36 hours), which complicates dose adjustments and increases accumulation risk 1
- Never prescribe methadone without experience - refer to pain specialists or palliative care if unfamiliar with methadone management 1
Comprehensive Assessment Required
Switching should not be a mere mathematical calculation but must include evaluation of: 1
- Underlying clinical situation and pain characteristics
- Current pain and adverse effect intensity
- Comorbidities (especially cardiac and renal function)
- Concomitant medications and potential drug interactions
- Pharmacokinetic factors that could limit drug effectiveness 1
Alternative Considerations
If methadone fails or is contraindicated, consider switching to: 3
- Fentanyl (transdermal or parenteral) - safer in renal disease 1, 2
- Hydromorphone - with careful renal monitoring 2
- Buprenorphine (transdermal) - safer in renal disease 1
Long-Term Management
Once stabilized on methadone, serum concentrations remain stable over months without significant autoinduction of metabolism. 4 Minor dose adjustments may be needed, but major changes are uncommon after initial titration. 4, 6
Success rates: Approximately 59-75% of patients switched to methadone from other opioids achieve good pain relief, though 24% may discontinue due to adverse effects. 6, 7